1. Remission of HIV-related naïve and high-risk Burkitt's lymphoma treated by autologous stem cell transplantation plus cART.
- Author
-
Min, Haiyan, Yang, Jianwei, Wang, Sanbin, Tao, Pengfei, Song, Yuqin, Wang, Xiaopei, Li, Huiqin, Yang, Xinping, Dong, Xingqi, Wang, Fu-Sheng, Shi, Ming, Wang, Xicheng, and Xu, Ruonan
- Subjects
BURKITT'S lymphoma ,HIV infection prognosis ,HIV infection risk factors ,DRUG resistance ,STEM cell transplantation - Abstract
A 27-year-old male with HIV-associated naïve and high-risk Burkitt's lymphoma sequentially received short-term, high-dose non-myeloablative chemotherapy and autologous CD34-positive stem cell transfusion in the setting of combined antiretroviral therapy (cART). Prompt hematopoietic recovery was observed after 2 weeks and clinical remission from Burkitt's lymphoma within approximately 30 months after transplantation. The HIV RNA load was inhibited persistently, and drug resistance was not observed. The CD4+ T cell count approached 323 cells/μL in a recent follow-up study. This case suggests that the use of intensive non-myeloablative chemotherapy with transplantation, combined with antiretroviral therapy, in HIV-related naive and high-risk Burkitt's lymphoma was tolerated and safe. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF